M Fareed1, K Suri, Adnan I Qureshi. 1. Zeenat Qureshi Stroke Research Center, Departments of Neurology, University of Minnesota, MN, USA, and Hennepin County Medical Center, Minneapolis, MN, USA.
Abstract
BACKGROUND: While results of clinical trials are used to impact practice among patients with ischemic stroke, very little information is available regarding proportion and characteristics of patients recruited in clinical trials in general practice. METHODS: We performed this analysis to provide an audit of recruitment in clinical trials among patients with acute ischemic stroke using data from the University Healthsystems Consortium benchmarking project. A review of 40 consecutive ischemic stroke cases meeting inclusion criteria and discharge within a 6-month period was conducted in 32 hospitals. RESULTS: A total of 1256 patients (mean age 67 years, range 18--99 years) were included. A total of 77 (6%) patients were recruited in clinical trials; 33 and 14 patients recruited in drug or device trials, respectively. In the multivariate analysis, age under 80 years (odd ratio [OR] 2.2, 95% confidence interval [CI] 1.0--4.9), white or African-American race as compared with others (OR 2.5, 95% CI 0.98--6.6), evaluation by a neurologist or stroke team (OR 14.8, 95% CI 2.0--108), the use of intravenous thrombolysis (OR 8.4, 95% CI 4.9--14.4), and history of hypertension (OR 1.9, 95% CI 1.0--3.4) were associated with recruitment in clinical trials. There was no relationship between patient's gender and recruitment in clinical trials. The rate of intracranial hemorrhage (6% vs 2%, p<0.05) and progression of stroke (12% vs 3%, p<0.05) were higher among those recruited in clinical trials. CONCLUSIONS: Patients recruited in clinical trials appear to have different characteristics from those who are not recruited limiting the generalizability of results from current trials.
BACKGROUND: While results of clinical trials are used to impact practice among patients with ischemic stroke, very little information is available regarding proportion and characteristics of patients recruited in clinical trials in general practice. METHODS: We performed this analysis to provide an audit of recruitment in clinical trials among patients with acute ischemic stroke using data from the University Healthsystems Consortium benchmarking project. A review of 40 consecutive ischemic stroke cases meeting inclusion criteria and discharge within a 6-month period was conducted in 32 hospitals. RESULTS: A total of 1256 patients (mean age 67 years, range 18--99 years) were included. A total of 77 (6%) patients were recruited in clinical trials; 33 and 14 patients recruited in drug or device trials, respectively. In the multivariate analysis, age under 80 years (odd ratio [OR] 2.2, 95% confidence interval [CI] 1.0--4.9), white or African-American race as compared with others (OR 2.5, 95% CI 0.98--6.6), evaluation by a neurologist or stroke team (OR 14.8, 95% CI 2.0--108), the use of intravenous thrombolysis (OR 8.4, 95% CI 4.9--14.4), and history of hypertension (OR 1.9, 95% CI 1.0--3.4) were associated with recruitment in clinical trials. There was no relationship between patient's gender and recruitment in clinical trials. The rate of intracranial hemorrhage (6% vs 2%, p<0.05) and progression of stroke (12% vs 3%, p<0.05) were higher among those recruited in clinical trials. CONCLUSIONS:Patients recruited in clinical trials appear to have different characteristics from those who are not recruited limiting the generalizability of results from current trials.
Authors: Yince Loh; D Kim; Z-S Shi; S Tateshima; P M Vespa; N R Gonzalez; S Starkman; J L Saver; R Jahan; D S Liebeskind; G R Duckwiler; F Viñuela Journal: AJNR Am J Neuroradiol Date: 2010-04-15 Impact factor: 3.825
Authors: H M Hussein; A L Georgiadis; G Vazquez; J T Miley; M Z Memon; Y M Mohammad; G A Christoforidis; N Tariq; A I Qureshi Journal: AJNR Am J Neuroradiol Date: 2010-01-14 Impact factor: 3.825
Authors: C P Hunter; R W Frelick; A R Feldman; A R Bavier; W H Dunlap; L Ford; D Henson; D Macfarlane; C R Smart; R Yancik Journal: Cancer Treat Rep Date: 1987-06
Authors: P S Reynolds; C T Crenshaw; D S Lefkowitz; B J Shelton; J S Preisser; C H Tegeler Journal: J Stroke Cerebrovasc Dis Date: 2001 Sep-Oct Impact factor: 2.136
Authors: Ashfaq Shuaib; Kennedy R Lees; Patrick Lyden; James Grotta; Antonio Davalos; Stephen M Davis; Hans-Christoph Diener; Tim Ashwood; Warren W Wasiewski; Ugochi Emeribe Journal: N Engl J Med Date: 2007-08-09 Impact factor: 91.245